Is the new Congress readyWEBINAR
to lower drug costs?With STAT’s Washington Correspondents,
Lev Facher and Nicholas Florko
Agenda
1. The Midterms
2. The Trump Administration
3. Legislation to Watch
4. Investigations
5. Lobbying
The Midterms
Slide 4
GOP holds Senate, Dems gain 40 House seats
Senate Majority Leader Mitch McConnell (R-Ky.) Speaker of the House Nancy Pelosi (D-Calif.)
Slide 5
The House Ways & Means Committee
Rep. Richard Neal (D-Mass.) Rep. Lloyd Doggett (D-Texas)
Slide 6
The House Energy & Commerce Committee
Rep. Anna Eshoo (D-Calif.) Rep. Frank Pallone (D-N.J.)
Slide 7
The House Energy & Commerce Committee
“We are going to do at least one diabetes hearing.”
Rep. Diana DeGette (D-Colo.)
Slide 8
House Freedom Caucus
The House Oversight Committee
Jim Jordan Mark Meadows Justin Amash
Paul Gosar Jody Hice
Michael Cloud Ralph Norman
Chip Roy Mark Green
Elijah Cummings Carolyn Maloney
Lacy Clay Jamie Raskin
Katie Hill Peter Welch
Mark DeSaulnierBrenda Lawrence
Ro KhannaJimmy Gomez
Alexandria Ocasio-CortezAyanna Pressley
Rashida Tlaib
House Progressive Caucus
Slide 9
Senate Finance Committee
Sen. Chuck Grassley (R-Iowa) Sen. Ron Wyden (D-Ore.)
Slide 10
Bipartisan Collaboration on SFC
“This legislation is a significant step forward to fixing the problems in our health care system that have allowed pharmaceutical manufacturers to price gouge taxpayers and consumers for too long.” —Sen. Grassley on the Right Rebate Act of 2018, co-sponsored with Wyden
Slide 11
The Senate HELP Committee
Sen. Lamar Alexander (R-Tenn.) Sen. Mitt Romney (R-Utah)
Slide 12
Sen. Lindsey Graham (R-S.C.)
The Senate Judiciary Committee
The Trump Administration
Slide 14
Joe Grogan, Chair, Domestic Policy Council Former Head of Federal Affairs, Gilead
Shahira Knight, White House Director of Legislative Affairs
The White House
Slide 15
Alex Azar, HHS SecretaryFormer President, Lilly USA
John O’Brien, Senior Advisor to the Secretary for Drug Pricing Reform
Dept. of Health and Human Services
Legislation to Watch
Slide 17
Legislation that will be taken seriously
→ Reforms for Medicare Part D
→ CREATES Act
→ Preserve Access to Affordable Generics Act
(Pay for Delay)
Slide 18
Messaging from 2020 candidates
→ Bernie Sanders’ international price index
→ Elizabeth Warren’s generic drug manufacturing bill
→ Klobuchar & Harris’ bill to block price increases
→ Various iterations of Medicare negotiation
→ Klobuchar, Brown & Harris’ drug exclusivity bill
Slide 19
Wild cards
→ Grassley-Klobuchar personal drug importation
→ PBM transparency bills
→ Cassidy-Warner value-based pricing bill
→ Wyden’s bill requiring justification for price spikes
→ Wyden-Grassley bill on Medicaid rebates
Investigations
Slide 21
Members & Companies Impacted
Senate FinanceAbbVie, AstraZeneca, Bristol-Myers Squibb,
Johnson & Johnson, Merck & Co., Pfizer, Sanofi, Eli Lilly,
Novo Nordisk
House OversightAstraZeneca, Teva,
Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt,
Amgen, Pfizer, Novo Nordisk, Sanofi, AbbVie
House Energy & Commerce
Sanofi, Eli Lilly, Novo Nordisk
Source: Giphy
Lobbying
Slide 24
Annual Lobbying by PhRMA
‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16 ‘17 ‘18
$6M
$12M
$18M
$24M
$30M
$0M
YEAR
TOTA
L
Slide 25
Other groups to watch
Q&A
Thanks!@levfacher @NicholasFlorko